Related Experiment Video
Updated: Oct 14, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
Could prevention of infantile spasms have been possible in a historical cohort of 31 tuberous sclerosis patients?
1University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, Postal Address: Yliopistonranta 1, FI-70110, Kuopio, Finland.
Insights
Preventing epilepsy in infants with tuberous sclerosis complex (TSC) is challenging. Early diagnosis of TSC is crucial for potential preventive treatment, but often delayed, hindering intervention effectiveness.
Area of Science:
- Neurology
- Genetics
- Pediatrics
Background:
- Tuberous sclerosis complex (TSC) is a genetic disorder.
- Infantile spasms (IS) are common in TSC patients.
- Preventing epilepsy in TSC infants is a key clinical goal.
Purpose of the Study:
- To evaluate the feasibility of preventing epilepsy in infants with TSC.
- To identify obstacles to early diagnosis and intervention.
Main Methods:
- Retrospective chart review of 31 TSC patients with IS.
- Analysis of clinical history, early development, TSC signs, seizure onset, EEG, and treatment response.
- Evaluation of brain imaging and other TSC-related organ manifestations.
Main Results:
- Most TSC infants had normal early development before spasms.
- Hypsarrhythmia or modified hypsarrhythmia was common on initial EEGs.
- Early diagnosis of TSC was possible in only one case (neonatal rhabdomyoma).
- Subependymal periventricular lesions were present in all patients at IS onset.
Conclusions:
- Preventive treatment for epileptic discharges in TSC is difficult due to diagnostic delays.
- Early TSC diagnosis, particularly with neonatal rhabdomyoma, offers a potential window for intervention.
- Improving early detection of TSC is essential for effective epilepsy prevention strategies.
Abstract:
Efforts to prevent epilepsy in infants with tuberous sclerosis complex (TSC) has been the focus of EPISTOP.
Purpose:
The present study was carried out to evaluate whether prevention could have been realistic.
Methods:
A retrospective analysis by hospital chart review of 31 patients with TSC and infantile spasms (practically all patients) admitted to two tertiary hospitals, Children's Hospital, University of Helsinki and Kuopio in 1980-2000. Clinical history, early cognitive development, early clinical signs of TSC, clinical signs of suspicious seizures, first seizures and EEG, response to adrenocorticotropic hormone (ACTH) therapy, EEG and brain imaging were evaluated.
Results:
Early development prior the spasms was apparently normal in 25 (80%). The first EEG ever performed for a child showed hypsarrhythmia in 16 (51%) or modified hypsarrhythmia in 10 (32%). Treatment lag was short (0-4, mean 2 weeks) and the primary response to ACTH favorable in 19 (64%). Etiological diagnostic workup of IS revealed TSC. In one single case (3%) the diagnosis of TSC could be made at birth due to a congenital cardiac rhabdomyoma. Three other rhabomyomas were diagnosed later. In brain imaging, subependymal periventricular calcifications or hypodense areas were seen in every patient at onset of IS. Other organ manifestations of TSC were retinal phakomas (6), polycystic kidneys (2), and renal angiolipomatosis (1).
Conclusions:
Preventive treatment of epileptic discharges could have been possible in a single case of neonatal rhabdomyoma suggesting that preventive treatment is challenging in everyday practice. The main obstacle is the delay of TSC diagnosis.
More Related Videos
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
10:58TMS: Using the Theta-Burst Protocol to Explore Mechanism of Plasticity in Individuals with Fragile X Syndrome and Autism
Published on: December 28, 2010
Related Concept Videos
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Skeletal Muscle Relaxants: Therapeutic Uses